BCR First Exon Sequences Specifically Activate the BCR/ABL Tyrosine Kinase Oncogene of Philadelphia ChromosomePositive Human Leukemias

REFERENCES

• Ben-Neriah, Y., A. Bernards, M. Paskind, G. Q. Daley, and D. Baltimore. 1986. Alternative 5′ exons in c-abl mRNA. Cell 44:577–586.
   PubMedGoogle Scholar
• Bergold, P. J., J. A. Blumenthal, E. D’Andrea, H. W. Snyder, L. Lederman, A. Silverstone, H. Nguyen, and P. Besnier. 1987. Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert. J. Virol. 61:1193–1202.
   PubMedGoogle Scholar
• Chen, S. J., Z. Chen, J. D. Grausz, J. Hillion, L. d’Auriol, G. Flandrin, C.-J. Larsen, and R. Berger. 1988. Molecular cloning of a 5′ segment of the genomic phl gene defines a new breakpoint cluster region (bcr2) in Philadelphia-positive acute leukemias. Leukemia 2:634–641.
   PubMed Web of Science ®Google Scholar
• Clark, S. S., W. M. Crist, and O. N. Witte. 1989. Molecular pathogenesis of Ph-positive leukemias. Annu. Rev. Med. 40:113–122.
   PubMed Web of Science ®Google Scholar
• Coulier, F., D. Martin-Zanca, M. Ernst, and M. Barbacid. 1989. Mechanism of activation of the human trk oncogene. Mol. Cell Biol. 9:15–23.
   PubMedGoogle Scholar
• Daley, G. Q., J. McLaughlin, O. N. Witte, and D. Baltimore. 1987. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH-3T3 fibroblasts. Science 237:532–535.
   PubMed Web of Science ®Google Scholar
• Daley, G. Q., R. Van Etten, and D. Baltimore. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830.
   PubMed Web of Science ®Google Scholar
• Denny, C. T., N. Shah, S. Ogden, C. Willman, T. McConnell, W. Crist, A. Carroll, and O. N. Witte. 1989. Localization of preferential sites of rearrangement within the BCR gene in Philadelphia chromosome positive acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 86:4254–4258.
   PubMedGoogle Scholar
• Downward, J., R. Riehl, L. Wu, and R. Weinberg. 1990. Identification of a nucleotide exchange-promoting activity for p21ras. Proc. Natl. Acad. Sci. USA 87:5998–6002.
   PubMed Web of Science ®Google Scholar
• Elefanty, A. G., I. K. Hariharan, and S. Cory. 1990. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9:1069–1078.
   PubMed Web of Science ®Google Scholar
• Ellis, C., M. Moran, F. McCormick, and T. Pawson. 1990. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature (London) 343:377–381.
   PubMed Web of Science ®Google Scholar
• Fainstein, E., M. Einat, E. Gokkel, C. Marcelle, C. M. Croce, R. P. Gale, and E. Canaani. 1989. Nucleotide sequence analysis of human abl and bcr-abl cDNAs. Oncogene 4:1477–1481.
   PubMed Web of Science ®Google Scholar
• Franz, W. M., P. Berger, and J. Y. J. Wang. 1989. Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8:137–147.
   PubMed Web of Science ®Google Scholar
• Groffen, J., J. R. Stephenson, N. Heisterkamp, A. de Klein, C. R. Bartam, and G. Grosveld. 1984. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93–99.
   PubMed Web of Science ®Google Scholar
• Hall, C. V., P. E. Jacob, G. M. Ringold, and F. Lee. 1983. Expression and regulation of Escherichia coli lacZ gene fusions in mammalian cells. J. Mol. Appl. Genet. 2:101–109.
   PubMedGoogle Scholar
• Hamaguchi, M., C. Grandori, and H. Hanafusa. 1988. Phosphorylation of cellular proteins in Rous sarcoma virus-infected cells: analysis by use of antiphosphotyrosine antibodies. Mol. Cell. Biol. 8:3035–3042.
   PubMedGoogle Scholar
• Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42–52.
   PubMed Web of Science ®Google Scholar
• Heisterkamp, N., G. Jenster, J. ten Hoeve, D. Zovich, P. Pattengale, and J. Groffen. 1990. Acute leukaemia in bcr/abl transgenic mice. Nature (London) 344:251–253.
   PubMed Web of Science ®Google Scholar
• Hirai, H., and H. E. Varmus. 1990. Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src. Mol. Cell. Biol. 10:1307–1318.
   PubMed Web of Science ®Google Scholar
• Hunter, T. 1987. A tail of two src’s: mutatis mutandis. Cell 49:1–4.
   PubMed Web of Science ®Google Scholar
• Jackson, P., and D. Baltimore. 1989. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8:449–456.
   PubMed Web of Science ®Google Scholar
• Kato, J.-Y., T. Takeya, C. Grandori, H. Iba, J. B. Levy, and H. Hanafusa. 1986. Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol. Cell. Biol. 6:4155—4160.
   PubMed Web of Science ®Google Scholar
• Kelliher, M. A., J. McLaughlin, O. N. Witte, and N. Rosenberg. 1990. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and bcr/abl. Proc. Natl. Acad. Sci. USA 87:6649–6653.
   PubMed Web of Science ®Google Scholar
• Kirschmeier, P. T., G. M. Housey, M. D. Johnson, A. S. Perkins, and I. B. Weinstein. 1988. Construction and characterization of a retroviral vector demonstrating efficient expression of cloned cDNA sequences. DNA 7:219–225.
   PubMedGoogle Scholar
• Konopka, J. B., and O. N. Witte. 1985. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell. Biol. 5:3116–3123.
   PubMed Web of Science ®Google Scholar
• Landau, N. R., and D. R. Littman. Unpublished data.
   Google Scholar
• Lebkowski, J. S., R. B. DuBridge, E. A. Antell, K. S. Greisen, and M. P. Calos. 1984. Transfected DNA is mutated in monkey, mouse, and human cells. Mol. Cell. Biol. 4:1951–1960.
   PubMed Web of Science ®Google Scholar
• Lifshitz, B., E. Fainstein, C. Marcelle, E. Shtivelman, R. Amson, R. P. Gale, and E. Canaani. 1988. bcr genes and transcripts. Oncogene 2:113–117.
   PubMedGoogle Scholar
• Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265–275.
   PubMed Web of Science ®Google Scholar
• Lugo, T. G., A.-M. Pendergast, A. J. Muller, and O. N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079–1082.
   PubMed Web of Science ®Google Scholar
• Lugo, T. G., and O. N. Witte. 1989. The BCR-ABL oncogene transforms Rat 1 cells and cooperates with v-myc. Mol. Cell. Biol. 9:1263–1270.
   Google Scholar
• Martin-Zanca, D., S. H. Hughes, and M. Barbacid. 1986. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (London) 319:743–748.
   PubMed Web of Science ®Google Scholar
• Mayer, B. J., M. Hamaguchi, and H. Hanafusa. 1988. A novel viral oncogene with structural similarity to phospholipase C. Nature (London) 332:272–275.
   PubMed Web of Science ®Google Scholar
• McLaughlin, J., E. Chianese, and O. N. Witte. 1987. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 84:6558–6562.
   PubMed Web of Science ®Google Scholar
• McLaughlin, J., E. Chianese, and O. N. Witte. 1989. Alternative forms of the BCR/ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol. Cell. Biol. 9:1866–1874.
   PubMed Web of Science ®Google Scholar
• Mes-Masson, A.-M., J. McLaughlin, G. Q. Daley, M. Paskind, and O. N. Witte. 1986. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA 83:9768-9772.
   PubMed Web of Science ®Google Scholar
• O’Brian, M. C., Y. Fukui, and H. Hanafusa. 1990. Activation of the proto-oncogene p60c-src by point mutations in the SH2 domain. Mol. Cell. Biol. 10:2855–2862.
   PubMedGoogle Scholar
• Pawson, T. 1988. Non-catalytic domains of cytoplasmic proteintyrosine kinases: regulatory elements in signal transduction. Oncogene 3:491–495.
   PubMed Web of Science ®Google Scholar
• Potts, W. M., A. B. Reynolds, T. J. Lansing, and J. T. Parsons. 1989. Activation of pp60c-src transforming potential by mutations altering the structure of an amino terminal domain containing residues 90-95. Oncogene Res. 3:343–355.
   Google Scholar
• Prywes, R., J. C. Foulkes, N. Rosenberg, and D. Baltimore. 1983. Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell 34:569–579.
   PubMedGoogle Scholar
• Rein, A., M. R. McClure, N. R. Rice, R. B. Luftig, and A. M. Schultz. 1986. Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc. Natl. Acad. Sci. USA 83:7246–7250.
   PubMed Web of Science ®Google Scholar
• Rosenberg, N., and O. N. Witte. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35:39–81.
   PubMed Web of Science ®Google Scholar
• Sadowski, I., J. C. Stone, and T. Pawson. 1986. A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of fuji- nami sarcoma virus P130gag-fps. Mol. Cell. Biol. 6:4396–4408.
   PubMed Web of Science ®Google Scholar
• Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463–5467.
   PubMed Web of Science ®Google Scholar
• Schiff-Maker, P. L., M. C. Burns, J. B. Konopka, S. Clark, O. N. Witte, and N. Rosenberg. 1986. Monoclonal antibodies specific for v-abl and c-abl encoded molecules. J. Virol. 57:1182–1186.
   PubMedGoogle Scholar
• Sefton, B. M., I. S. Trowbridge, J. A. Cooper, and E. M. Scolnick. 1982. The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus, and Abelson virus contain tightly bound lipid. Cell 31:465–474.
   PubMed Web of Science ®Google Scholar
• Shields, A., O. N. Witte, E. Rothenberg, and D. Baltimore. 1978. High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections. Cell 14:601–609.
   PubMedGoogle Scholar
• Shtivelman, E., B. Lifshitz, R. P. Gale, and E. Canaani. 1985. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature (London) 315:550–554.
   PubMed Web of Science ®Google Scholar
• Shtivelman, E., B. Lifshitz, R. P. Gale, B. A. Roe, and E. Canaani. 1986. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47:277–284.
   PubMed Web of Science ®Google Scholar
• Smith, M. R., S. J. DeGudicibus, and D. W. Stacey. 1986. Requirement for c-ras proteins during viral oncogene transformation. Nature (London) 320:540–543.
   PubMed Web of Science ®Google Scholar
• Soekarman, D., J. van Denderen, L. Hoefsloot, M. Moret, T. Meeuwsen, J. van Baal, A. Hagemeijer, and G. Grosveld. 1990. A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 4:397–403.
   PubMed Web of Science ®Google Scholar
• Stahl, M. L., C. R. Ferenz, K. L. Kellerher, R. W. Kriz, and J. L. Knopf. 1988. Sequence similarity of phospholipase C with the non-catalytic region of src. Nature (London) 332:269–272.
   PubMed Web of Science ®Google Scholar
• Takebe, Y., M. Seiki, J.-I. Fujisawa, P. Hoy, K. Yokota, K.-I. Arai, M. Yoshida, and N. Arai. 1988. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8:466–472.
   PubMed Web of Science ®Google Scholar
• Wagner, E. F., M. Vanek, and B. Vennstrom. 1985. Transfer of genes into embryonal carcinoma cells by retrovirus infection: efficient expression from an internal promoter. EMBO J. 4:663-666.
   Google Scholar
• Watanabe, S. M., and O. N. Witte. 1983. Site-directed deletions of Abelson murine leukemia virus define 3′ sequences essential for transformation and lethality. J. Virol. 45:1028–1036.
   PubMedGoogle Scholar
• Whitlock, C. A., and O. N. Witte. 1982. Long term culture of B lymphocytes and their precursors from murine bone marrow. Proc. Natl. Acad. Sci. USA 79:3608–3612.
   PubMed Web of Science ®Google Scholar
• Ziegler, S. F., C. A. Whitlock, S. F. Goff, A. Gifford, and O. N. Witte. 1981. Lethal effect of the Abelson murine leukemia virus transforming gene product. Cell 27:477–486.
   PubMedGoogle Scholar